Advertisement

Topics

Kite first to submit CAR-T therapy in Europe

07:35 EDT 1 Aug 2017 | PharmaTimes

Kite Pharma has submitted the first CAR-T cell therapy in Europe, seeking permission to market its axicabtagene ciloleucel (axi-cel) to treat patients with three subtypes of aggressive non-Hodgkin lymphoma (NHL).

Original Article: Kite first to submit CAR-T therapy in Europe

NEXT ARTICLE

More From BioPortfolio on "Kite first to submit CAR-T therapy in Europe"

Quick Search
Advertisement
 

Relevant Topic

Hodgkin lymphoma
Hodgkin Lymphoma is a  disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be limited to a single lymph node region (Stage 1) or spread...